Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
ZNTL Stock Chart & Stats
$1.41
-$0.17(-5.69%)
At close: 4:00 PM EST
$1.41
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.01 - $3.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)716.92K
Market Cap
$253.60M
Enterprise Value-$178.60M
Total Cash (Recent Filing)$280.70M
Total Debt (Recent Filing)$36.71M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Mar 04, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding72,250,780
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.64
Price to Sales (P/S)3.19
P/FCF Ratio-1.26
Enterprise Value/Market Cap-0.70
Enterprise Value/Revenue-6.65
Enterprise Value/Gross Profit-6.71
Enterprise Value/Ebitda1.23
Forecast
1Y Price Target
$6.60Price Target Upside368.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker Strategy And Unmet NeedFocused Cyclin E1 biomarker strategy targets a clear unmet medical need in Cyclin E1-positive platinum-resistant ovarian cancer, creating a defined patient population that could facilitate targeted development and uptake.
Clinical EfficacyReproducible clinical activity of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer suggests meaningful benefit versus standard chemotherapy, supporting commercial differentiation if confirmed.
Pipeline Expansion And CombinationsPlanned mechanistic combinations with other therapies and exploration in additional tumor types can broaden the potential market opportunity beyond gynecologic cancers and diversify future revenue pathways.
Bears Say
Clinical Development And Enrollment RiskExecution challenges in enrolling confirmatory trials and completing randomized comparisons could delay potential approvals and prolong investor uncertainty.
Regulatory And Approval RiskDependence on trial outcomes and subsequent regulatory review creates a material approval risk that could trigger significant stock volatility if results do not meet regulatory expectations.
Single-asset Concentration RiskHeavy reliance on azenosertib as the lead asset tied to a specific biomarker concentrates company value, exposing investors to steep downside if the program encounters setbacks.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.01 and its highest was $3.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $253.60M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 47 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.528 by $0.158.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.43.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 72,250,780 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.528. Following the earnings report the stock price went up 6.061%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.60 (368.09% Upside)
$6.60 (368.09% Upside)
Hedge Fund Trend
Increased
By 51.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 21.2%
Last 30 Days ▲ 37.4%
Last 30 Days ▲ 37.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
-49.18%
Trailing 12-Months
Asset Growth
-28.47%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector, leveraging its expertise in medicinal chemistry and translational science to develop drug candidates aimed at improving patient outcomes in oncology. Zentalis' core products include a pipeline of proprietary agents designed to address unmet medical needs in cancer treatment.
ZNTL Stock 12 Month Forecast
Average Price Target
$6.60
▲(368.09% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
13.06% Insiders
6.12% Mutual Funds
33.96% Other Institutional Investors
42.91% Public Companies and
Individual Investors